Working... Menu
Trial record 68 of 177 for:    HIV Post Exposure

The Impact of Mentor Mothers on PMTCT Service Outcomes in Nigeria (MoMent)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01936753
Recruitment Status : Completed
First Posted : September 6, 2013
Last Update Posted : September 18, 2018
University of Maryland
Federal Ministry of Health, Nigeria
Information provided by (Responsible Party):
Dr. Nadia Sam-Agudu, Institute of Human Virology, Nigeria

Brief Summary:

Nigeria has significant challenges in the delivery and coverage of PMTCT (Prevention of mother-to-child transmission of HIV) services. Only 30% of pregnant women living with HIV are provided anti-retroviral drugs for PMTCT. Less than 10% of HIV-exposed infants receive HIV testing for early diagnosis by age 2 months. Furthermore, an unacceptably high number of women with HIV who are enrolled in PMTCT programs do not complete them. In other words, uptake and retention in PMTCT programs in Nigeria is not adequate. Ultimately, mother-to-child transmission of HIV is high, resulting in a high number of new child HIV infections.

Mentor Mothers (MMs) are women living with HIV who provide peer support to other HIV-positive women. MM programs have been incorporated into PMTCT programs in several African countries with some success, but with varying levels of MM training and program structure. The MoMent (MOther MENTor) study investigates whether highly-structured MM programs will further improve uptake and successful completion of PMTCT services (eg testing and appointments) in Nigeria. The study also evaluates the impact of structured MM programs on other outcomes, including facility deliveries, new infant HIV infections, infant survival and maternal viral suppression. Rural areas are the focus of this study because of their particularly poor performance in PMTCT coverage and outcomes.

Condition or disease Intervention/treatment Phase
HIV Behavioral: Trained Mentor Mother and Supervisor Not Applicable

Detailed Description:

Nigeria has had a national HIV/AIDS care and treatment program in place since 2003. Included in this national program are prevention programs; the largest of which is the prevention-of-mother-to-child transmission (PMTCT) program. Despite more than 10 yrs of providing PMTCT, Nigeria still has significant problems with uptake of, and retention in these services. Only 30% of HIV-positive pregnant women receive HIV drugs for both treatment and prophylaxis, and Nigeria has an estimated 41,000 new child infections annually, the highest of any country in the world.

Mentor Mothers (MM) are women living with HIV who are experienced users and navigators of HIV services, particularly PMTCT. Public health interventions engaging MM to support other HIV-positive women for linkage and retention in PMTCT and treatment services has been tested in South Africa, and has been adopted and applied in several other African countries. Similar MM programs have also been adopted and implemented in Nigeria since 2007; however, objective evaluations of MM impact on PMTCT service uptake and retention have not been performed to date.

While MM and similar peer support interventions have shown some success in other African countries, their implementation between and within countries has not been standardized. Incremental impact may be gained with more structured, objective-specific MM programming and service delivery.

The MoMent (MOther MENTor) is an implementation research study that is evaluating the impact of structured vs routine peer support on PMTCT outcomes in Nigeria, focusing on two North-Central states, the Federal Capital Territory and Nasarawa. The intervention consists of a simple but detailed standardized training curriculum for MMs coupled with daily MM supervision by dedicated personnel as well as standardized, user-friendly tools for both MMs and their supervisors to use for service delivery. These trained MM, along with trained MM Supervisors, form the basis of the Mentor Mother Intervention package. The choice of rural areas served by Primary Healthcare Centers is due to the fact that PMTCT coverage and uptake is lowest in these areas; the study sites are located in hard-to-reach-areas where a significant number of PMTCT-eligible clientele live.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 497 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a prospective paired cohort study
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Impact of Mentor Mother Programmes on PMTCT Service Uptake and Retention at Primary Healthcare Facilities in Nigeria
Actual Study Start Date : April 24, 2014
Actual Primary Completion Date : November 30, 2016
Actual Study Completion Date : November 1, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Mentor Mother Peer Support
This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
Behavioral: Trained Mentor Mother and Supervisor
Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.

No Intervention: Routine Peer Support
Pregnant HIV-positive women receive standard-of-care PMTCT services (drugs, appointments, tests). These women are, per routine, assigned peer counselors who are also HIV-positive women with PMTCT experience but who do receive little or no standardized formal training, and are not closely supervised.

Primary Outcome Measures :
  1. Proportion of HIV-exposed infants presenting for DNA PCR testing by 2 months of age. [ Time Frame: At 2 months (62 days) of age for the HIV-exposed infant. ]
    Early infant diagnosis (EID) is defined as the collection and processing of an HIV DNA PCR test for an HIV-exposed infant by 2 months of age. EID is done to ensure that HIV-positive infants will be promptly enrolled into HIV treatment programs and can start lifesaving Antiretroviral Therapy (ART) in timely fashion.

  2. Proportion of HIV-positive mothers retained in PMTCT care at 6 months post-delivery. [ Time Frame: At 180 days (6 months) post-delivery ]
    Maternal retention is determined by evaluating for at least 1 clinic visit made for each 30-day period for the first 180 days postpartum. The proportion of women making at least 3 of 6 monthly appointments are designated retained; this proportion is calculated for each study arm.

Secondary Outcome Measures :
  1. Maternal viral suppression at 6 months postpartum [ Time Frame: 6 months (169 to 197 days) post-delivery ]
    Proportion of HIV-positive mothers with undetectable viral load (<20 copies/ml), measured at 6 months postpartum.

  2. Proportion of infants HIV-positive at 2 and 6 months post-delivery. [ Time Frame: At 2 months (62 days) and at 6 months (197 days) post-delivery. ]
    All exposed infants who tested positive by DNA-PCR at 6 - 8 weeks of age and at 6 months are included in analysis for "early" MTCT and "late" MTCT, respectively. Any infants testing positive at first/early DNA PCR are excluded for testing at 6 months of age.

  3. Proportion of HIV-positive mothers retained in PMTCT care at 12 months post-delivery. [ Time Frame: At 360 days (12 months) post-delivery ]
    Maternal retention is determined by evaluating for at least 1 clinic visit made for each 30-day period for the first 360 days postpartum. The proportion of women making at least 6 of 12 monthly appointments are designated retained; this proportion is calculated for each study arm.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Only HIV-positive pregnant females are eligible for recruitment. All infants born live to these females are also enrolled.
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pregnant and HIV-positive
  • 15 years of age and above

Exclusion Criteria:

  • Working or ever worked as a Mentor Mother
  • Presenting in labor
  • Does not plan to continue receiving services at study site

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01936753

Layout table for location information
Nadia Sam-Agudu
Abuja, FCT, Nigeria
Sponsors and Collaborators
Institute of Human Virology, Nigeria
University of Maryland
Federal Ministry of Health, Nigeria
Layout table for investigator information
Principal Investigator: Nadia A Sam-Agudu, MD, CTropMed Institute of Human Virology, Nigeria; University of Maryland School of Medicine

Publications of Results:

Other Publications:
Layout table for additonal information
Responsible Party: Dr. Nadia Sam-Agudu, Senior Techical Advisor, Pediatric and Adolescent HIV, Institute of Human Virology, Nigeria Identifier: NCT01936753     History of Changes
Other Study ID Numbers: IHVN_WHO_PMTCT_MoMent
RPC531 ( Other Grant/Funding Number: World Health Organization )
First Posted: September 6, 2013    Key Record Dates
Last Update Posted: September 18, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Dr. Nadia Sam-Agudu, Institute of Human Virology, Nigeria:
Mentor Mothers